- Home
- TOPP vs CMMB Comparison
TOPP vs CMMB Comparison
Compare TOPP & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPP
- CMMB
- Stock Information
- Founded
- TOPP 2014
- CMMB 2004
- Country
- TOPP United States
- CMMB Israel
- Employees
- TOPP N/A
- CMMB N/A
- Industry
- TOPP
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- TOPP
- CMMB Health Care
- Exchange
- TOPP NYSE
- CMMB Nasdaq
- Market Cap
- TOPP 39.8M
- CMMB 32.2M
- IPO Year
- TOPP 2025
- CMMB N/A
- Fundamental
- Price
- TOPP $2.29
- CMMB $1.71
- Analyst Decision
- TOPP
- CMMB Strong Buy
- Analyst Count
- TOPP 0
- CMMB 2
- Target Price
- TOPP N/A
- CMMB $9.00
- AVG Volume (30 Days)
- TOPP 85.4K
- CMMB 835.3K
- Earning Date
- TOPP 01-01-0001
- CMMB 03-06-2025
- Dividend Yield
- TOPP N/A
- CMMB N/A
- EPS Growth
- TOPP N/A
- CMMB N/A
- EPS
- TOPP 0.02
- CMMB N/A
- Revenue
- TOPP $15,873,843.00
- CMMB N/A
- Revenue This Year
- TOPP N/A
- CMMB N/A
- Revenue Next Year
- TOPP N/A
- CMMB N/A
- P/E Ratio
- TOPP $115.13
- CMMB N/A
- Revenue Growth
- TOPP N/A
- CMMB N/A
- 52 Week Low
- TOPP $1.63
- CMMB $0.58
- 52 Week High
- TOPP $4.50
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- TOPP N/A
- CMMB 32.89
- Support Level
- TOPP N/A
- CMMB $1.66
- Resistance Level
- TOPP N/A
- CMMB $2.06
- Average True Range (ATR)
- TOPP 0.00
- CMMB 0.16
- MACD
- TOPP 0.00
- CMMB -0.04
- Stochastic Oscillator
- TOPP 0.00
- CMMB 9.43
About TOPP TOPPOINT HOLDINGS INC
Toppoint Holdings Inc is a truckload services and solutions provider focused on the recycling export supply chain.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.